PrEP Descovy Oral denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Descovy for PrEP as "Not FDA-Approved" — and Why You Can Appeal

Descovy (emtricitabine/tenofovir alafenamide) is FDA-approved for HIV pre-exposure prophylaxis (PrEP). A denial on "not FDA-approved" grounds is almost always a claims-processing error — either the submitted diagnosis or procedure codes did not correctly reflect the approved PrEP indication, an outdated drug policy was applied, or a formulary system was not updated to reflect the FDA approval. This is among the most straightforward denial types to overturn on appeal because the documentary evidence — the FDA label — is publicly available and unambiguous.

### Why This Is Appealable

An insurer cannot deny an FDA-approved drug for its FDA-approved indication on the basis that it is not FDA-approved. Doing so is a factual error, not a clinical judgment call. If the plan is subject to the ACA's preventive-services mandate, coverage of Descovy for PrEP without cost-sharing may also be independently required because PrEP carries a USPSTF Grade A recommendation.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/marketplace plans), you have the right to a full and fair internal review. File within the deadline shown on your denial notice.
• External review: After a final internal denial, you may request Independent Review Organization (IRO) review within approximately four months under ACA §2719. An IRO applies accepted medical and regulatory standards; FDA approval is a bright-line fact.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — typically decided within 72 hours.

### Documentation to Gather

1. FDA-approved prescribing label for Descovy — download directly from the FDA's DailyMed database. Highlight the PrEP indication section. This is the single dispositive document for this denial type. 2. FDA approval history — include the approval date and the specific indication as stated in the label. This demonstrates the approval predates the denial. 3. Prescriber letter — confirming the prescription is for the FDA-approved PrEP indication, that the patient is HIV-negative, and that the submitted claim codes correspond to that indication. 4. Coding review — have the prescriber's billing staff confirm the diagnosis and NDC codes submitted were correct for the PrEP indication. A coding correction may resolve the denial before a formal appeal is needed. 5. UHC policy document cited in the denial — request the specific policy. If it predates Descovy's PrEP approval or incorrectly characterizes the indication, note the discrepancy explicitly.

### Criteria-Mapping Structure

For this denial type, the criteria-mapping can be concise: list UHC's stated reason for the denial, then provide the FDA label section, approval date, and indication text that directly contradicts it. Attach the FDA label as Exhibit A. The appeal letter itself should be brief and factual — this is a documentation dispute, not a clinical argument.

### Common Resolution Path

Many "not FDA-approved" denials for Descovy resolve at the internal appeal stage or even at a pre-appeal phone call with UHC, once the FDA label is presented. Before filing a formal appeal, call UHC member services, ask them to confirm the specific policy or system rule that generated the denial, and reference the FDA approval date. Document the call (date, representative name, reference number). If the denial is not rescinded on that basis, proceed with the written internal appeal.

### Next Step

Obtain the FDA label from DailyMed, confirm the codes with the prescriber, and file the internal appeal with the label attached. If unresolved, external review with an IRO is a strong option given the factual clarity of FDA approval.